18 February 2025 - Alvotech and Teva Pharmaceuticals today announced that the US FDA has accepted for review a biologics license application for AVT06, Alvotech’s proposed biosimilar to Eylea (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness.

The process to obtain regulatory approval is anticipated to be completed in the fourth quarter of 2025.

Read Alvotech press release